DAFTAR PUSTAKA

1. Yoga I Kasjmir, Kusworini Handono, Linda Kurniaty Wijaya, Laniyati

Hamijoyo, Zuljasri Albar, Handono Kalim, Hermansyah.et, al.
Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan
Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi
Indonesia. Jakarta: 2011;3.

2. Mariana Postal, Lilian TL Costallat, and Simone Appenzeller. Biological

Therapy in Systemic Lupus Erythematosus. Hindawi Publishing
Corporation International Journal of Rheumatology.Brazil:2012;1-9.

3. Wahyuni, Sri. Peran Imunitas Humoral pada Penyakit Systemic Lupus

Erytematosus. Fakultas Kedokteran Universitas Malikussaleh. 2010.

4. Kajsmir YI, et al. Diagnosis dan Pengelolaan Lupus Eritematosus

Sistemik. Rekomendasi. Perhimpunan Reumatologi Indonesia 2011.

5. Bertsias G., Cervera R., Boumpas DT. Systemic Lupus Erythematosus:

Pathogenesis and Clinical Features.2012. Tersedia di:
URL:http://eular.org. Diakses pada 27 november 2019.

6. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. The

lancet 2014. 1-11.

7. Mak A, dan Tay SH. Environmental Factors, Toxicants and Systemic

Lupus Erythematosus. Int. J. Mol. Sci: 2014;(15) halaman 16043-16056.

8. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin

Pathol: 2003; (56) halaman 481–490.

9. Gatto M, et al,. Emerging and critical issues in the pathogenesis of lupus.

Autoimmun Rev.2012.

10. Magro, Rosalio. Biological therapies and their clinical impact in the
treatment of systemic lupus erythematosus. Ther Adv Musculoskel Dis:
2019;Vol. 11: 1–9.

26
11. Giuseppe Murdaca, Barbara Maria Colombo, Francesco Puppo. Emerging
biological drugs: A new therapeutic approach for Systemic Lupus
Erythematosus. An update upon efficacy and adverse events.
Autoimmunity Reviews: 2011;(11) 56–60.

12. Stohl, William. Future prospects in biologic therapy for systemic lupus
erythematosus. Nat. Rev. Rheumatol. 2013.

13. Reddy, Venkat., Jayne, David., Close, David., Isenberg, David. B-cell
depletion in SLE: clinical and trial experience with rituximab and
ocrelizumab and implications for study design. Arthritis Research &
Therapy: 2013;15.

14. M. Haubitz. New and emerging treatment approaches to lupus.Biologics. :

2010;(4) 263-271.

15. C. Ding, S. Foote, and G. Jones. B-cell-targeted therapy for systemic

lupus erythematosus: an update. BioDrugs: 2008;(22) no 4 halaman 239-
249.

16. F. Perosa, E. Favoino, M. A. Caragnano, M. Prete, and F. Dammacco.

CD20: a target antigen for immunotherapy of autoimmune diseases.
Autoimmunity Reviews: 2005;(4) no 8 halaman 526–531.

17. A. J. Grillo-L ´opez, C. A. White, B. K. Dallaire et al. Rituximab: the first

monoclonal antibody approved for the treatment of lymphoma. Current
Pharmaceutical Biotechnology: 2000; (1) no 1 1-9.

18. Dominik Samotij and Adam Reich. Biologics in the Treatment of Lupus
Erythematosus. BioMed Research International:2019;1-17.

19. Haubitz,M. New and emerging treatment approaches to lupus. Biologics:

Targets & Therapy: 2010;(4) 263–271.

20. Aisha Lateefa,b and Michelle Petria. Biologics in the treatment of

systemic lupus erythematosus. Current Opinion in Rheumatology 22:504–
509.

21. Jean-François Kleinmann, Florence Tubach, Veronique Le Guern, Alexis

Mathian, Christophe Richez, et al. International and multidisciplinary
expert recommendations for the use of biologics in systemic lupus
erythematosus. Autoimmunity Reviews, Elsevier: 2017;16 (6), pp.650-
657.

27
22. Gunnarson, iva., et.al. Biologicals for the treatment of systemic lupus
erythematosus. Annals of Medicine: 2012; 44 hal 225–232.

23. Gatto, Mariele., et.al. In-/off-label use of biologic terapy in systemic lupus
erythematosus.BMC Medicine: 2014;12:30.

28